Title: Targets for Tumor Growth Inhibition
Patent Number: 7,781,414
Filed: April 1, 2004 PCT Filed: April 1, 2004
Lead Inventor: Patrick Lu, Intradigm (Silence Therapeutics)
The invention, the patent's abstract states, "relates to methods for treating cancers by manipulating a target gene expression by up-regulation, silencing, and/or down-regulation of the gene, such as EGFR-RP, TRA1, MFGE8, TNFSF13, and ZFP236, respectively. The methods are useful in treating cancers and/or inhibiting tumor growth by enhancing expression of a gene that is validated as a target, such as ICT1030, for protein, peptide drug, and gene therapy modalities; or by RNA interference to silence and/or down-regulate targets, such as ICT1024, ICT1025 … ICT1031, and ICB1003 that are validated for antibody, small molecule, and other inhibitor drug modalities."
Title: Process for Delivering siRNA to Cardiac Muscle Tissue
Patent Number: 7,781,415
Filed: Feb. 3, 2004
Lead Inventor: Hans Herweijer, Roche
The patent claims "a process for delivering a polynucleotide to a cardiac tissue cell in a mammal … [by] introducing a composition consisting of a polynucleotide into a blood vessel and increasing permeability of the blood vessel to the polynucleotide. The polynucleotide can be a small interfering RNA or microRNA, and [can] inhibit gene expression in the cell."
Title: siRNA Targeting Tumor Protein 53
Patent Number: 7,781,575
Filed: Sept. 18, 2009
Lead Inventor: Anastasia Khvorova, Dharmacon (Thermo Fisher Scientific)
"Efficient sequence-specific gene silencing is possible through the use of siRNA technology," the patent's abstract states. "By selecting particular siRNAs by rational design, one can maximize the generation of an effective gene-silencing reagent, as well as methods for silencing genes. Methods, compositions, and kits generated through rational design of siRNAs are disclosed."
Title: Targeted Delivery of siRNA
Application Number: 20100209440
Filed: Jan. 25, 2008 PCT Filed: Jan. 25, 2008
Lead Inventor: Premlata Shankar, Immune Disease Institute (Harvard University)
The invention, the patent application's abstract states, "provides a method of delivering RNA interference molecules to a cell or a cell in a subject [by] … contacting the cell with a protein-double stranded RNA complex."
The protein portion of the complex comprises "a targeting moiety, which will specifically bind to a site on a target cell, and a binding moiety linked thereto, which will bind to the double-stranded RNA," it adds. "The double stranded RNA segment is [then] delivered to a cell and effects RNA interference of the target RNA in the cell."
Title: Nicked or Gapped Nucleic Acid Molecules and Uses Thereof
Application Number: 20100209487
Filed: Oct. 18, 2007 PCT Filed: Oct. 18, 2007
Lead Inventor: Steven Quay, Nastech Pharmaceutical (Marina Biotech)
The invention, the patent application's abstract states, comprises "meroduplex — nicked or gapped — ribonucleic acid molecules that decrease or silence target gene expression. An mdRNA of this disclosure comprises at least three strands that combine to form at least two non-overlapping double-stranded regions separated by a nick or gap wherein one strand is complementary to a target gene RNA. In addition, the meroduplex may have one or more modifications or substitutions, such as nucleotide base, sugar, terminal cap structure, internucleotide linkage, or any combination of such modifications. Also provided are methods of decreasing expression of a target gene in a cell or in a subject to treat a disease related to altered expression of a target gene."
Title: Method for Enhancing Serum Stability and Lowering Immune Response of siRNA Down-Regulating Gene Expression of HBV or HCV
Application Number: 20100209491
Filed: May 8, 2008 PCT Filed: May 8, 2008
Lead Inventor: Soo In Kim, Mogam Biotechnology Research Institute
The invention, the patent application's abstract states, is "a method for enhancing the serum stability and lowering the immunostimulatory property of a small interfering ribonucleic acid, which mediates RNA interference against a viral gene expression of hepatitis B virus or hepatitis C virus."
Titles: RNAi Inhibition of Alpha-ENaC Expression
Application Numbers: 20100210513, 20100210514
Filed: April 30, 2010
Lead Inventor: Gino Van Heeke, Novartis
The inventions relate to "compositions and methods for modulating the expression of alpha-ENaC, and more particularly to the down-regulation of alpha-ENaC expression by chemically modified oligonucleotides," the patent applications' abstracts state.
Title: Therapeutic siRNA Molecules for Reducing VEGFR1 Expression In Vitro and In Vivo
Application Number: 20100210710
Filed: Oct. 10, 2008 PCT Filed: Oct. 10, 2008
Lead Inventor: Frank Xie, Intradigm (Silence Therapeutics)
"The invention relates to nucleic acid molecule compositions for use in modulating the expression and activity of VEGF pathway genes and decreasing unwanted neovascularization, including tumor angiogenesis, by RNA interference and methods and compositions comprising the nucleic acid molecules," the patent application's abstract states.